Cancer vaccine - CancerVax

Drug Profile

Cancer vaccine - CancerVax

Alternative Names: C-VAX; CancerVax; Canvaxin; MCV; Melanoma vaccine - CancerVax; Melanoma vaccine - John Wayne Cancer Institute; PMCV

Latest Information Update: 05 Oct 2005

Price : $50

At a glance

  • Originator CancerVax Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Colorectal cancer; Malignant melanoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 05 Oct 2005 Discontinued - Phase-II for Colorectal cancer in USA (Intradermal)
  • 05 Oct 2005 Discontinued - Phase-III for Malignant melanoma in Australia (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top